PURPOSE: Clinical practice guidelines (CPGs) recommend adjuvant chemotherapy after curative-intent surgery for colorectal cancer (CRC). Studies have shown variable rates of adherence to adjuvant therapy CPGs. This study sought to determine the proportion of patients in Nova Scotia receiving CPG-concordant adjuvant chemotherapy within 12 weeks of surgery for CRC in 2001 to 2005, and to identify factors associated with chemotherapy receipt beyond 12 weeks from surgery or chemotherapy nonreceipt. METHODS: Patients with stages IIB or III colon or stages II or III rectal cancer who underwent curative-intent surgery in Nova Scotia were identified through the provincial cancer registry and anonymously linked to 14 administrative health databases. Chart review was conducted to obtain chemotherapy data and reasons for chemotherapy nonreceipt. Logistic regression was used to identify factors independently associated with receipt of chemotherapy and meeting the 12-week benchmark (P < .05). RESULTS: A total of 1,151 patients were identified, of whom 59% received chemotherapy. Factors predicting chemotherapy receipt were male sex, age < 75 years, no hospital readmission within 30 days of surgery, stage III disease, no prior cancer diagnosis, and rectal cancer. Of the 679 patients who received chemotherapy, 479 (72%) met the 12-week benchmark, with male sex, urban residence, less social deprivation, colon cancer and increased length of hospital stay as significant factors. Of the 472 patients who did not receive chemotherapy, the most common reason for nonreceipt was no consultation with a medical oncologist (53%). CONCLUSION: A number of factors influence adherence to adjuvant chemotherapy CPGs for CRC and should be incorporated in future work as novel regimens enter clinical practice.
PURPOSE: Clinical practice guidelines (CPGs) recommend adjuvant chemotherapy after curative-intent surgery for colorectal cancer (CRC). Studies have shown variable rates of adherence to adjuvant therapy CPGs. This study sought to determine the proportion of patients in Nova Scotia receiving CPG-concordant adjuvant chemotherapy within 12 weeks of surgery for CRC in 2001 to 2005, and to identify factors associated with chemotherapy receipt beyond 12 weeks from surgery or chemotherapy nonreceipt. METHODS:Patients with stages IIB or III colon or stages II or III rectal cancer who underwent curative-intent surgery in Nova Scotia were identified through the provincial cancer registry and anonymously linked to 14 administrative health databases. Chart review was conducted to obtain chemotherapy data and reasons for chemotherapy nonreceipt. Logistic regression was used to identify factors independently associated with receipt of chemotherapy and meeting the 12-week benchmark (P < .05). RESULTS: A total of 1,151 patients were identified, of whom 59% received chemotherapy. Factors predicting chemotherapy receipt were male sex, age < 75 years, no hospital readmission within 30 days of surgery, stage III disease, no prior cancer diagnosis, and rectal cancer. Of the 679 patients who received chemotherapy, 479 (72%) met the 12-week benchmark, with male sex, urban residence, less social deprivation, colon cancer and increased length of hospital stay as significant factors. Of the 472 patients who did not receive chemotherapy, the most common reason for nonreceipt was no consultation with a medical oncologist (53%). CONCLUSION: A number of factors influence adherence to adjuvant chemotherapy CPGs for CRC and should be incorporated in future work as novel regimens enter clinical practice.
Authors: Deirdre P Cronin; Linda C Harlan; Arnold L Potosky; Limin X Clegg; Jennifer L Stevens; Margaret M Mooney Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: Jennifer L Malin; Katherine L Kahn; John Adams; Lorna Kwan; Marianne Laouri; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2002-06-05 Impact factor: 13.506
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Debrah A Wirtzfeld; Lynn Mikula; Robert Gryfe; Pietro Ravani; Elizabeth L Dicks; Pat Parfrey; Steve Gallinger; William G Pollett Journal: Can J Surg Date: 2009-04 Impact factor: 2.089
Authors: Selwyn O Rogers; John Z Ayanian; Clifford Y Ko; Katherine L Kahn; Alan M Zaslavsky; Robert S Sandler; Nancy L Keating Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: Kevin M Gorey; Isaac N Luginaah; Emma Bartfay; GuangYong Zou; Sundus Haji-Jama; Eric J Holowaty; Caroline Hamm; Sindu M Kanjeekal; Frances C Wright; Madhan K Balagurusamy; Nancy L Richter Journal: Health Soc Work Date: 2013-11
Authors: Robin Urquhart; Cynthia Kendell; Gordon Buduhan; Daniel Rayson; Joan Sargeant; Paul Johnson; Eva Grunfeld; Geoffrey A Porter Journal: CMAJ Open Date: 2016-01-12
Authors: Arielle E Kanters; Arden M Morris; Paul H Abrahamse; Lona Mody; Pasithorn A Suwanabol Journal: Dis Colon Rectum Date: 2018-07 Impact factor: 4.585
Authors: Robin Urquhart; Cynthia Kendell; Joan Sargeant; Gordon Buduhan; Paul Johnson; Daniel Rayson; Eva Grunfeld; Geoffrey A Porter Journal: Implement Sci Date: 2012-10-25 Impact factor: 7.327
Authors: Kevin M Gorey; Sindu M Kanjeekal; Frances C Wright; Caroline Hamm; Isaac N Luginaah; Emma Bartfay; Guangyong Zou; Eric J Holowaty; Nancy L Richter Journal: Int J Equity Health Date: 2015-10-29